Vaccination

Sorrento Announces Selection of T-VIVA-19™ as Targeted Protein Vaccine Candidate for SARS-CoV-2

Wednesday, July 1, 2020 - 5:06pm

T-VIVA-19 (targeted virus vaccine against COVID-19) is a recombinant fusion protein of the SARS-CoV-2 spike protein S1 domain and human IgG Fc.

Key Points: 
  • T-VIVA-19 (targeted virus vaccine against COVID-19) is a recombinant fusion protein of the SARS-CoV-2 spike protein S1 domain and human IgG Fc.
  • Novel protein to progress as priority vaccine candidate development program.
  • T-VIVA-19 is a recombinant fusion protein of the spike protein S1-domain and the Fc portion of the human IgG1 antibody (rS1-Fc).
  • Immunization with the rS1-Fc protein via intramuscular and intravenous injections induced antibodies against the SARS-CoV-2 protein in all mice within the first week of administration.

Analysis of the Emerging Disease Landscape: Novel Coronavirus (COVID-19) - May 2020 - ResearchAndMarkets.com

Wednesday, July 1, 2020 - 1:20pm

The "Analysis of the Emerging Disease Landscape - COVID-19 - May 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Analysis of the Emerging Disease Landscape - COVID-19 - May 2020" report has been added to ResearchAndMarkets.com's offering.
  • The epidemiology of COVID-19 is rapidly evolving and a number of companies have begun to invest in this space.
  • The absence of proven therapeutic options and the lack of a vaccine to protect against infection has led to a race to develop effective interventions.
  • A range of players - from pharma and biotech firms to academic institutions and government agencies - have thrown their hats in the ring.

Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial

Wednesday, July 1, 2020 - 11:00am

In addition, pandemic influenza, such as the H1N1 Swine Flu pandemic of 2009, is a constant global threat.

Key Points: 
  • In addition, pandemic influenza, such as the H1N1 Swine Flu pandemic of 2009, is a constant global threat.
  • BiondVax (NASDAQ: BVXV) is a Phase 3 clinical stage biopharmaceutical company developing a universal flu vaccine.
  • In a total of seven completed Phase 1/2 and Phase 2 clinical trials enrolling 818 participants, the vaccine has been shown to be safe, well-tolerated, and immunogenic.
  • The ongoing pivotal Phase 3 clinical trial aims to assess safety and effectiveness of M-001 in reducing flu illness and severity.

Intravacc to In-license CimCure's iBoost Technology, Expanding its Vaccine Platform Portfolio

Wednesday, July 1, 2020 - 8:00am

This technology also enables Intravacc to expand its translational expertise towards the development of cancer vaccines.

Key Points: 
  • This technology also enables Intravacc to expand its translational expertise towards the development of cancer vaccines.
  • iBoost is currently applied to elicit antibody responses against the tumor vasculature, a strategy that conquers the problem of drug resistance.
  • By using the patented iBoost technology, Intravacc and CimCure are also involved in the joint development of a COVID-19 vaccine.
  • Intravacc also has its own proprietary vaccine platform, and established state-of-the-art research and (GMP) production facilities.

Intravacc to In-license CimCure's iBoost Technology, Expanding its Vaccine Platform Portfolio

Wednesday, July 1, 2020 - 8:01am

This technology also enables Intravacc to expand its translational expertise towards the development of cancer vaccines.

Key Points: 
  • This technology also enables Intravacc to expand its translational expertise towards the development of cancer vaccines.
  • iBoost is currently applied to elicit antibody responses against the tumor vasculature, a strategy that conquers the problem of drug resistance.
  • By using the patented iBoost technology, Intravacc and CimCure are also involved in the joint development of a COVID-19 vaccine.
  • Intravacc also has its own proprietary vaccine platform, and established state-of-the-art research and (GMP) production facilities.

COVID-19 Rapid Summary: Immune response and vaccine development

Wednesday, July 1, 2020 - 12:05am

The House of Lords Science and Technology Committee is producing rapid summaries of oral evidence sessions, aimed at providing the public with the latest information on the Science of COVID-19.

Key Points: 
  • The House of Lords Science and Technology Committee is producing rapid summaries of oral evidence sessions, aimed at providing the public with the latest information on the Science of COVID-19.
  • This summary covers two evidence panels on Tuesday 23 June, where we heard from experts including those leading key vaccine development projects in the UK, about the immune response to the virus and the development of vaccines.

COVID-19 Rapid Summary: Immune response and vaccine development

Wednesday, July 1, 2020 - 12:05am

The House of Lords Science and Technology Committee is producing rapid summaries of oral evidence sessions, aimed at providing the public with the latest information on the Science of COVID-19.

Key Points: 
  • The House of Lords Science and Technology Committee is producing rapid summaries of oral evidence sessions, aimed at providing the public with the latest information on the Science of COVID-19.
  • This summary covers two evidence panels on Tuesday 23 June, where we heard from experts including those leading key vaccine development projects in the UK, about the immune response to the virus and the development of vaccines.

New Strategy Emerges for Vaccine Against Methicillin-Resistant Staphylococcal aureus

Tuesday, June 30, 2020 - 3:00pm

The new vaccination strategy, developed by researchers at NYU Grossman School of Medicine, targets toxic molecules released by all Staphylococcal bacteria, called leukocidins, rather than directly targeting the bacteria.

Key Points: 
  • The new vaccination strategy, developed by researchers at NYU Grossman School of Medicine, targets toxic molecules released by all Staphylococcal bacteria, called leukocidins, rather than directly targeting the bacteria.
  • Attempts to develop a Staphylococcal vaccine have so far failed, researchers say, in part because leukocidins kill immune system cells, or leukocytes, needed by the immune system to fight the infection and whose production is triggered by a vaccine.
  • "This strategy is based on maximum disarmament of the bacterium's ability to kill all types of immune system cells."
  • Torres says a "foolproof" vaccine against the bacteria, including MRSA, will likely involve targeting more than just its leukocidin toxins.

Meissa Vaccines Provides a Pipeline Update on Vaccine Candidates for COVID-19 and RSV

Tuesday, June 30, 2020 - 2:00pm

These initial clinical data support the further development of MV-012-968 for RSV and the application of Meissas technology to a COVID-19 vaccine candidate.

Key Points: 
  • These initial clinical data support the further development of MV-012-968 for RSV and the application of Meissas technology to a COVID-19 vaccine candidate.
  • Meissas COVID-19 vaccine candidate, MV-014-210, was developed on the companys codon deoptimized RSV vaccine platform with the goal of creating safe, potent, stable, and cost-effective intranasal vaccines.
  • Meissas COVID-19 vaccine candidate, MV-014-210, was derived by modifying the companys RSV LAV candidate, MV-012-968, replacing the RSV glycoproteins with a functioning SARS-CoV-2 Spike protein.
  • Furthermore, building our COVID-19 vaccine candidate on our RSV vaccine platform provides safety advantages compared to a live attenuated coronavirus approach.

Novavax Expands Executive Leadership and Announces Key Promotions

Monday, June 29, 2020 - 1:42pm

In addition, I also want to congratulate John, John, and Jill on their promotions as they are all a critical part of Novavax growth.

Key Points: 
  • In addition, I also want to congratulate John, John, and Jill on their promotions as they are all a critical part of Novavax growth.
  • He was most recently Chief Executive Officer of rare disease company Vtesse, before its acquisition by Sucampo Pharmaceuticals, Inc., now a part of Mallinckrodt.
  • Additionally, he was responsible for development of MedImmunes H1N1 influenza vaccine, which was the first to be approved by FDA.
  • In 2014, Mr. Trizzino rejoined Novavax and in 2018 was promoted to Chief Business Officer and Chief Financial Officer.